<DOC>
	<DOCNO>NCT00629018</DOCNO>
	<brief_summary>Several study document transplantation bone marrow-derived cell ( BMC ) follow acute myocardial infarction associate reduction infarct scar size improvement leave ventricular function perfusion . The available evidence human suggest BMC transplantation associate improvement physiologic anatomic parameter acute myocardial infarction chronic ischemic heart disease , beyond conventional therapy . In particular , intracoronary application BMC prove safe associate significant improvement leave ventricular ejection fraction ( LVEF ) patient chronic heart failure . In contrast ischemic heart failure , data effect BMC transplantation patient dilate cardiomyopathy limited pre-clinical study . In rat model dilate cardiomyopathy , intramyocardial delivery pluripotent mesenchymal cell improve LVEF , possibly induction myogenesis angiogenesis , well inhibition myocardial fibrosis , suggest beneficial effect stem cell transplantation dilate cardiomyopathy may primarily relate ability supply large amount angiogenic , antiapoptotic , mitogenic factor . Similarly , transplantation cocultured mesenchymal stem cell skeletal myoblasts show improve LVEF murine model Chagas disease . Study Aim : To define clinical effect BMC transplantation dilate cardiomyopathy pilot clinical study investigate effect intracoronary CD34+ cell transplantation functional , structural , neurohormonal , electrophysiologic parameter patient end-stage dilated cardiomyopathy .</brief_summary>
	<brief_title>Safety Efficacy Study Stem Cell Transplantation Treat Dilated Cardiomyopathy</brief_title>
	<detailed_description>Patients randomly allocate 1:1 ratio receive intracoronary transplantation autologous CD34+ stem cell ( SC group ) intracoronary infusion ( control group ) . At time enrollment , yearly interval thereafter , perform detailed clinical evaluation , echocardiography , 6-minute walk test , measure plasma level NT-proBNP . To better-define potential role inflammatory response , also measure plasma inflammatory marker ( tumor necrosis factor [ TNF ] -Î± interleukin [ IL ] -6 ) time CD34+ stem cell injection .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Normal coronary angiogram Left ventricular ejection fraction &lt; 40 % NYHA III IV heart failure symptoms Bone marrow reactivity ( GCSF test ) Presence viable myocardium Hematologic malignancy Multiorgan failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Stem Cells</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Dilated Cardiomyopathy</keyword>
</DOC>